No Data
Tempest Therapeutics Reports Q3 2024 Financial Results
Tempest Therapeutics Is Maintained at Overweight by Piper Sandler
Tempest Therapeutics Shares Are Trading Lower After the Company Reported Worse-than-expected Q3 EPS Results.
Piper Sandler Maintains Tempest Therapeutics(TPST.US) With Buy Rating, Cuts Target Price to $5
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Scotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)
No Data
No Data